AVEO Oncology Announces Webcast of Presentation at the 39th Annual J.P. Morgan Healthcare Conference
January 05 2021 - 7:00AM
Business Wire
AVEO Oncology (Nasdaq: AVEO) today announced that Michael
Bailey, president and chief executive officer of AVEO, will present
at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday,
January 13, 2021 at 5:20 p.m. Eastern Time. Following the
presentation, Mr. Bailey will be joined by other members of AVEO’s
management team for a question-and-answer session.
A live webcast of the presentation and question-and-answer
session can be accessed by visiting the investors section of the
Company’s website at www.aveooncology.com. A replay of the webcast
will be archived for 30 days following the presentation date.
About AVEO Pharmaceuticals, Inc.
AVEO is an oncology-focused biopharmaceutical company committed
to delivering medicines that provide a better life for cancer
patients. AVEO’s strategy is to focus its resources toward
development and commercialization of its product candidates in
North America, while leveraging partnerships to support development
and commercialization in other geographies. AVEO’s lead candidate,
tivozanib, is approved as FOTIVDA® in the European Union and other
countries in the EUSA territory for the treatment of adult patients
with advanced renal cell carcinoma. Tivozanib is being studied in
the TIVO-3 trial, which is supporting a regulatory submission of
tivozanib in the U.S. seeking marketing approval as a treatment for
relapsed or refractory renal cell carcinoma. AVEO has previously
reported promising early clinical data on ficlatuzumab (anti-HGF
mAb) in head and neck cancer, acute myeloid leukemia and pancreatic
cancer and is conducting a randomized Phase 2 confirmatory clinical
trial of ficlatuzumab in head and neck cancer. AVEO’s earlier-stage
pipeline includes several monoclonal antibodies in oncology
development, including AV-203 (anti-ErbB3 mAb), AV-380 (anti-GDF15
mAb) and AV-353 (anti-Notch 3 mAb). AVEO is committed to creating
an environment of diversity and inclusion as a foundation for
innovation.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of AVEO
within the meaning of the Private Securities Litigation Reform Act
of 1995 that involve substantial risks and uncertainties. All
statements, other than statements of historical fact, contained in
this press release are forward-looking statements. Actual results
or events could differ materially due to a number of important
factors, including risks discussed in the section titled “Risk
Factors” in AVEO’s most recent Annual Report on Form 10-K, its
quarterly reports on Form 10-Q and its other filings with the SEC.
The forward-looking statements in this press release represent
AVEO’s views as of the date of this press release. AVEO anticipates
that subsequent events and developments may cause its views to
change. While AVEO may elect to update these forward-looking
statements at some point in the future, it specifically disclaims
any obligation to do so. You should, therefore, not rely on these
forward-looking statements as representing AVEO’s views as of any
date other than the date of this press release
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210105005230/en/
David Pitts, Argot Partners (212) 600-1902
aveo@argotpartners.com
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Aug 2024 to Sep 2024
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Sep 2023 to Sep 2024